Evommune gains funding to accelerate therapies for chronic inflammatory diseases
27 Apr 2023
Phase 2ImmunotherapyGene Therapy
Preview
Source: Pharmaceutical Technology
Evommune focuses on the development of therapies to treat chronic inflammatory diseases. Credit: MasterTux from Pixabay.
Evommune has received $50m in Series B financing to accelerate the development of therapies for the treatment of chronic inflammatory diseases.
Co-led by new investor Arix Bioscience and current investors EQT Life Sciences and SymBiosis, the financing round also included new and existing investors such as Amplitude Ventures.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Gene Therapy to Activate gp91phox for Chronic Granulomatous Disease GlobalData
Preview
Source: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: immunotherapy for neurodegenerative disease GlobalData
View all
Pivotal bioVenture Partners and Andera Partners also participated in the company’s Series A funding round.
Arix Bioscience managing director Mark Chin stated: “As a new investor in Evommune, we are excited to partner with the company’s experienced leadership team, which leverages a unique human tissue screening platform to curate its drug discovery and translational medicine decisions.”
The funding will allow Evommune to advance three prioritised pipeline programmes that are focused on inflammatory diseases.
One of these programmes includes EVO101, a novel small molecule inhibitor that specifically targets the interleukin 1 receptor-associated kinase 4 (IRAK4) gene.
EVO101 is currently under assessment in a Phase 2a proof-of-concept trial involving patients diagnosed with atopic dermatitis. The company plans to release data from the trial later in 2023.
The company is also assessing the preclinical molecule, EVO756, which is designed to selectively modulate MRGPRX2 and target mast cells to treat diseases such as chronic spontaneous urticaria and interstitial cystitis.
The firm’s pipeline also includes a discovery-stage programme focused on autoimmune diseases through PKCθ.
Evommune president and CEO Luis Peña stated: “Evommune has multiple value-creating milestones planned over the next two years. We appreciate the continued support of our existing investors, and welcome new investors who share the vision and excitement about our programmes to evolve the immunology landscape.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.